193 related articles for article (PubMed ID: 32157447)
1. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo.
Teck AT; Urban S; Quass P; Nelde A; Schuster H; Letsch A; Busse A; Walz JS; Keilholz U; Ochsenreither S
Cancer Immunol Immunother; 2020 Jul; 69(7):1217-1227. PubMed ID: 32157447
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.
Ochsenreither S; Majeti R; Schmitt T; Stirewalt D; Keilholz U; Loeb KR; Wood B; Choi YE; Bleakley M; Warren EH; Hudecek M; Akatsuka Y; Weissman IL; Greenberg PD
Blood; 2012 Jun; 119(23):5492-501. PubMed ID: 22529286
[TBL] [Abstract][Full Text] [Related]
3. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
Butterfield LH; Meng WS; Koh A; Vollmer CM; Ribas A; Dissette VB; Faull K; Glaspy JA; McBride WH; Economou JS
J Immunol; 2001 Apr; 166(8):5300-8. PubMed ID: 11290817
[TBL] [Abstract][Full Text] [Related]
4. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
5. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
6. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.
Andersen RS; Sørensen RB; Ritter C; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Immunol Immunother; 2011 Feb; 60(2):227-34. PubMed ID: 20981424
[TBL] [Abstract][Full Text] [Related]
7. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
8. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
[TBL] [Abstract][Full Text] [Related]
10. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
11. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
12. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.
Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y
J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272
[TBL] [Abstract][Full Text] [Related]
13. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
14. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
15. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
16. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
17. Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes.
Li J; Bai J; Gu L; He A; Wang J; Wang J; Zhang P; Zhang W
Med Oncol; 2014 Dec; 31(12):293. PubMed ID: 25355639
[TBL] [Abstract][Full Text] [Related]
18. HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin.
Lewis JW; Sewell A; Price D; Elliott T
Eur J Immunol; 1998 Oct; 28(10):3214-20. PubMed ID: 9808190
[TBL] [Abstract][Full Text] [Related]
19. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
20. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
